MX2020001768A - Metodos de tratamiento de la osteoartritis con gel de canabidiol transdermico. - Google Patents

Metodos de tratamiento de la osteoartritis con gel de canabidiol transdermico.

Info

Publication number
MX2020001768A
MX2020001768A MX2020001768A MX2020001768A MX2020001768A MX 2020001768 A MX2020001768 A MX 2020001768A MX 2020001768 A MX2020001768 A MX 2020001768A MX 2020001768 A MX2020001768 A MX 2020001768A MX 2020001768 A MX2020001768 A MX 2020001768A
Authority
MX
Mexico
Prior art keywords
osteoarthritis
methods
pharmaceutical composition
gel
canabidiol
Prior art date
Application number
MX2020001768A
Other languages
English (en)
Spanish (es)
Inventor
John Messenheimer
Nancy Tich
Donna Gutterman
Daniel Clauw
Original Assignee
Zynerba Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zynerba Pharmaceuticals Inc filed Critical Zynerba Pharmaceuticals Inc
Publication of MX2020001768A publication Critical patent/MX2020001768A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
MX2020001768A 2017-08-14 2018-08-13 Metodos de tratamiento de la osteoartritis con gel de canabidiol transdermico. MX2020001768A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762545468P 2017-08-14 2017-08-14
US201862661733P 2018-04-24 2018-04-24
PCT/IB2018/056090 WO2019034985A1 (en) 2017-08-14 2018-08-13 METHODS OF TREATING ARTHROSIS USING CANNABIDIOL TRANSDERMAL GEL

Publications (1)

Publication Number Publication Date
MX2020001768A true MX2020001768A (es) 2020-12-03

Family

ID=65362584

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020001768A MX2020001768A (es) 2017-08-14 2018-08-13 Metodos de tratamiento de la osteoartritis con gel de canabidiol transdermico.

Country Status (11)

Country Link
US (4) US20200170963A1 (https=)
EP (1) EP3668500A4 (https=)
JP (3) JP2020530857A (https=)
KR (1) KR20200054171A (https=)
AU (2) AU2018318425A1 (https=)
BR (1) BR112020003025A2 (https=)
CA (1) CA3072849A1 (https=)
IL (2) IL301622A (https=)
JO (1) JOP20200031A1 (https=)
MX (1) MX2020001768A (https=)
WO (1) WO2019034985A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020530857A (ja) * 2017-08-14 2020-10-29 ジナーバ・ファーマシューティカルズ・インコーポレイテッド 経皮カンナビジオールゲルを用いた変形性関節症の治療方法
CA3300266A1 (en) 2017-09-28 2026-03-02 Harmony Biosciences Management, Inc. Treatment of fragile x syndrome with cannabidiol
US12582664B2 (en) 2017-09-28 2026-03-24 Harmony Biosciences Management, Inc. Treatment of fragile x syndrome with cannabidiol
CA3122735A1 (en) 2018-12-14 2020-06-18 Zynerba Pharmaceuticals, Inc. Treatment of 22q11.2 deletion syndrome with cannabidiol
US12409131B2 (en) 2019-10-03 2025-09-09 Pike Therapeutics Usa, Inc. Transdermal delivery of dronabinol
AU2020358869A1 (en) 2019-10-03 2022-04-14 Pike Therapeutics Usa, Inc. Transdermal delivery of dronabinol
US12016829B2 (en) 2019-10-11 2024-06-25 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
EP4041209A4 (en) 2019-10-11 2024-01-24 Pike Therapeutics, Inc. TRANSDERMAL COMPOSITIONS COMPRISING CANNABIDIOL (CBD) FOR USE IN THE TREATMENT OF EPILEPTIC DISORDERS
EP4041210B1 (en) * 2019-10-13 2026-03-18 FibroBiologics, Inc. Combination of cannabidiol and fibroblasts for use in the treatment of disc degenerative disease
US12121617B2 (en) 2019-10-14 2024-10-22 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
US12268699B2 (en) 2019-10-14 2025-04-08 Pike Therapeutics Inc. Transdermal delivery of tetrahydrocannabinol
CA3155181A1 (en) 2019-10-14 2021-04-22 Pike Therapeutics, Inc., 1219014 B.C. Ltd. Transdermal delivery of cannabidiol
BR112022026044A2 (pt) * 2020-06-29 2023-03-07 Zynerba Pharmaceuticals Inc Tratamento de síndrome do x frágil com canabidiol
AU2022257344A1 (en) * 2021-04-12 2023-10-26 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
EP4098254A1 (en) * 2021-06-04 2022-12-07 Assistance Publique, Hopitaux De Paris Cannabidiol for use in the treatment of pain resulting from an indoleamine 2,3-dioxygenase-1 (ido1) related disease
JP2025535174A (ja) * 2022-10-17 2025-10-22 インベンテージ ラボ インコーポレイテッド 炎症性疾患の治療または予防のための徐放型注射用組成物およびその製造方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9807639D0 (en) * 1998-04-14 1998-06-10 Kennedy Rheumatology Inst Anti-inflammatory agents
US8449908B2 (en) * 2000-12-22 2013-05-28 Alltranz, Llc Transdermal delivery of cannabidiol
GB2414933B (en) * 2004-06-08 2009-07-15 Gw Pharma Ltd Cannabinoid compositions for the treatment of disease and/or symptoms in arthritis
EP1890727B1 (en) * 2005-05-25 2012-10-03 CaloSyn Pharma, Inc Method and composition for treating osteoarthritis
US20090247619A1 (en) * 2008-03-06 2009-10-01 University Of Kentucky Cannabinoid-Containing Compositions and Methods for Their Use
CN102271705A (zh) * 2008-12-22 2011-12-07 墨尔本大学 骨关节炎治疗
CA2760460C (en) * 2009-04-28 2019-04-02 Alltranz Inc. Transdermal formulations of cannabidiol comprising a penetration enhancer and methods of using the same
EP2424568A1 (en) * 2009-04-29 2012-03-07 University Of Kentucky Research Foundation Cannabinoid-containing compositions and methods for their use
PT2473475T (pt) * 2009-08-31 2017-08-02 Zynerba Pharmaceuticals Inc Utilização de profármacos de canabidiol na administração tópica e transdérmica com microagulhas
KR20150056522A (ko) * 2012-06-26 2015-05-26 앰버데일 엔터프라이지즈 피티와이 리미티드 초음파 공동화에 의한 지방 조직으로부터 줄기 세포의 분리 및 이의 이용 방법
EP3177286A4 (en) * 2014-07-18 2018-05-16 Medipath Inc. Compositions and methods for physiological delivery using cannabidiol
JP2020530857A (ja) * 2017-08-14 2020-10-29 ジナーバ・ファーマシューティカルズ・インコーポレイテッド 経皮カンナビジオールゲルを用いた変形性関節症の治療方法

Also Published As

Publication number Publication date
EP3668500A1 (en) 2020-06-24
IL272593A (en) 2020-03-31
JP2025024068A (ja) 2025-02-19
US20200170963A1 (en) 2020-06-04
JP2020530857A (ja) 2020-10-29
EP3668500A4 (en) 2021-04-28
IL301622A (en) 2023-05-01
US20250268843A1 (en) 2025-08-28
JP2023109969A (ja) 2023-08-08
CA3072849A1 (en) 2019-02-21
US20240189255A1 (en) 2024-06-13
JOP20200031A1 (ar) 2020-02-12
KR20200054171A (ko) 2020-05-19
AU2018318425A1 (en) 2020-02-27
JP7590803B2 (ja) 2024-11-27
BR112020003025A2 (pt) 2020-08-04
AU2024205778A1 (en) 2024-09-05
WO2019034985A1 (en) 2019-02-21
US20240148669A1 (en) 2024-05-09

Similar Documents

Publication Publication Date Title
MX2020001768A (es) Metodos de tratamiento de la osteoartritis con gel de canabidiol transdermico.
BR112018002046A2 (pt) métodos de tratamento da síndrome de lennox-gastaut usando fenfluramina
JOP20200082B1 (ar) علاج متلازمة الكروموسوم إكس الهش باستخدام الكانابيديول
CL2019003542A1 (es) Métodos de tratamiento para la fibrosis quística.
MX2023007212A (es) Formulaciones de pulverizacion de epinefrina.
MX2022003193A (es) Tratamiento de encefalopatia asociada al gen syngap1.
BR112017006113A8 (pt) usos de auristatina, composições farmacêuticas, formas de dosagem para o tratamento de câncer e kits.
CL2016001794A1 (es) Metodo para administrar tasimelteon a un paciente humano que incluye la administración oral de una dosis efectiva en condiciones de ayuno para tratar un trastorno del ritmo circadiano o un trastorno del sueño, como el trastorno del sueño-vigilia diferente a 24 horas no-24 metodo para acortar el tmax del tasimelteon en un paciente humano que está siendo tratado con tasimelteon.
EA202091112A1 (ru) Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение
CL2018002734A1 (es) Métodos de tratamiento con vitamina d
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
MX2020007462A (es) Metodos de tratamiento de enfermedades inflamatorias cronicas.
CL2024003729A1 (es) Terapia combinada de agente activo anti-pd-1, agente activo anti-tim-3 y agente activo anti-lag-3 para tratar cáncer.
WO2019010301A8 (en) Treatment of heart disease by inhibition of the action of muscle a-kinase anchoring protein (makap)
MX2021014523A (es) Metodos para tratar colangiocarcinoma.
MX2022001450A (es) Metodo de tratamiento del cancer.
ZA202002107B (en) Use of specific sirna against protein s for the treatment of hemophilia
MX2021001549A (es) Una composicion farmaceutica para el tratamiento seguro y efectivo del dolor de rodilla y/o cadera.
EA202091653A1 (ru) Миноциклин для лечения воспалительных заболеваний кожи
MX2024005220A (es) Endoxifeno para el tratamiento del cancer.
PH12018501769A1 (en) Medicament for treatment of diabetic foot infections
MX2022000082A (es) Composiciones terapeuticas y metodos para tratar canceres.
WO2020061067A8 (en) Compositions and methods for treating bone injury
BR102018006534A8 (pt) Métodos para melhorar a atividade dos retinoides
AR101227A1 (es) Combinaciones de un derivado de n-tiazolil-4-fenoxibencenosulfonamida y un agente farmacéuticamente activo seleccionado a partir de gabapentina y pregabalina para tratar dolor